Skip to main content
SpringerLink
Log in

Complementary and Alternative Medicine

  • Chapter
  • First Online:
Practical Cardiology

  • 1361 Accesses

Abstract

Complementary and alternative medical (CAM) therapies can be defined as medical treatments that are not currently used as standard medical treatments in conventional Western medicine. CAM therapies can be categorized in five major groups: alternative medical systems like naturopathy and acupuncture, mind-body interventions like meditation and hypnotherapy, manipulative and body-based methods like massage therapy and chiropractic, energy therapies like reiki and polarity therapy, and biologically based treatments like herbal remedies and chelation therapy. These types of treatments are not taught widely in United States medical schools and are generally unavailable at U.S. hospitals. However, surveys dating back to 1990 show that the use of CAM therapies has become increasingly more widespread in the United States. As such, the market for such treatments has grown exponentially. For example, a 2001 survey from the Josiah Macy, Jr., Foundation showed that nearly 50% of Americans were using CAM therapies with an estimated 600 million visits to CAM practitioners per year and an estimated market of $30 billion annually. Yet despite the increase in the usage of and expenditure on CAM therapies, many CAM users do not talk to their physicians about CAM treatments. The main reasons given for this are that patients are not aware that they should discuss CAM with their physicians and their physicians do not ask them about CAM therapies. Thus, it is increasingly important for practitioners to gain familiarity with various forms of CAM and to specifically elicit and document a history of CAM usage from patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Eisenberg DM, Kessler RC, Foster C, et al. Unconventional medicine in the United States. N Engl J Med. 1993;328:246–52.

    CAS  PubMed  Google Scholar 

  2. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990–1997. JAMA. 1998;280:1569–75.

    CAS  PubMed  Google Scholar 

  3. Hager M. Chairman’s Summary of the Conference Education of Health Professionals in Complementary/Alternative Medicine. Fishman AP, Chair. New York: Josiah Macy, Jr. Foundation; 2001.

    Google Scholar 

  4. Liu EH, Turner LM, Lin SH, et al. Use of alternative medicine by patients undergoing cardiac surgery. J Thorac Cardiovasc Surg. 2000;120:335–41.

    CAS  PubMed  Google Scholar 

  5. Barnes PM, Bloom B, Nahin R. Complementary and alternative medicine use among adults and children: United States, 2007. CDC National Health Statistics Report #12; 2008.

    Google Scholar 

  6. Nahin, RL, Barnes PM, Stussman BJ, Bloom B. Costs of Complementary and Alternative Medicine (CAM) and frequency of visits to CAM practitioners: United States, 2007. National health statistics reports; No 18. Hyattsville, MD: National Center for Health Statistics; 2009.

    Google Scholar 

  7. https://nccih.nih.gov/sites/nccam.nih.gov/files/NCCAM_SP_508.pdf

  8. http://nccam.nih.gov/

  9. Hemingway H, Marmot M. Evidence based cardiology: psychosocial factors in the aetiology and prognosis of coronary heart disease. Systematic review of prospective cohort studies. BMJ. 1999;318:1460–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Grunbaum JA, Vernon SW, Clasen CM. The association between anger and hostility and risk factors for coronary heart disease in children and adolescents: a review. Ann Behav Med. 1997;19:179–89.

    CAS  PubMed  Google Scholar 

  11. Linden W, Stossel C, Maurice J. Psychosocial interventions for patients with coronary artery disease: a meta-analysis. Arch Intern Med. 1996;156:745–52.

    CAS  PubMed  Google Scholar 

  12. Luskin FM, Newell KA, Griffith M, et al. A review of mind-body therapies in the treatment of cardiovascular disease: part 1; implication for the elderly. Altern Ther Health Med. 1998;3:46–52.

    Google Scholar 

  13. Dusek JA, Hibberd PL, Buczynski B, et al. Stress management versus lifestyle modification on systolic hypertension and medication elimination: a randomized trial. J Altern Complement Med. 2008;14(2):129–38.

    PubMed  Google Scholar 

  14. Casey A, Chang BH, Huddleston J, Virani N, Benson H, Dusek JA. A model for integrating a mind/body approach to cardiac rehabilitation: outcomes and correlators. J Cardiopulm Rehabil Prev. 2009;29(4):230–8.

    PubMed  Google Scholar 

  15. van Tudler MW, Koes BW, Bouter LM. Conservative treatment for acute and chronic non-specific low back pain: a systematic review of randomized controlled trials of the most common interventions. Spine. 1997;22:2128–56.

    Google Scholar 

  16. Sandefur R, Coulter ID. Licensure and legal scope of practice. In: Cherkin DC, Mootz RD, editors. Chiropractic in the United States: training, practice and research. Rockville, MD: U.S. Department of Health and Human Services, Agency for Health Care Policy and Research; 1997; AHCPR Pub. No. 98-N002.

    Google Scholar 

  17. Friedman RSC, Burg MM, Miles P, Lee F, Lampert R. Effects of Reiki on autonomic activity early after acute coronary syndrome. J Am Coll Cardiol. 2010;56(12):995–6.

    PubMed  Google Scholar 

  18. Church D, Hawk C, Brooks A, Toukolehto O, Wren M, Dinter I, Stein P. Psychological trauma in veterans using EFT (Emotional Freedom Techniques): a randomized controlled trial. Poster session at the 31st Annual Meeting & Scientific Sessions of the Society of Behavioral Medicine, Seattle, April 7–10, 2010; 2010.

    Google Scholar 

  19. http://nccam.nih.gov/health/acupuncture/

  20. http://nccam.nih.gov/clinical-trials/accupuncture.htm

  21. Warshafsky S, Kamer RS, Sivak SL. Effect of garlic on total serum cholesterol: a meta-analysis. Ann Intern Med. 1993;119:599–605.

    CAS  PubMed  Google Scholar 

  22. Silagy C, Neil A. Garlic as a lipid lowering agent—a meta-analysis. J Roy Coll Phys Lond. 1994;28:39–45.

    CAS  Google Scholar 

  23. Berthold HK, Sudhop T, von Bergmann K. Effect of a garlic oil preparation on serum lipoproteins and cholesterol metabolism: a randomized controlled trial. JAMA. 1998;279:1900–2.

    CAS  PubMed  Google Scholar 

  24. Piscitelli SC, Burstein AH, Welden N, et al. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis. 2002;34:234–8.

    PubMed  Google Scholar 

  25. Anderson JW, Johnstone BM, Cook-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med. 1995;333:276–82.

    CAS  PubMed  Google Scholar 

  26. Heber D, Yip I, Ashley JM, et al. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr. 1999;69:231–6.

    CAS  PubMed  Google Scholar 

  27. Singh RB, Niaz MA, Ghosh S. Hypolipidemic and antioxidant effects of Commiphora mukul as an adjunct to dietary therapy in patients with hypercholesterolemia. Cardiovasc Drugs Ther. 1994;8:659–64.

    CAS  PubMed  Google Scholar 

  28. Ararwal RC, Singh SP, Saran RK, et al. Clinical trial of gugulipid—a new hypolipidemic agent of plant origin in primary hyperlipidemia. Indian J Med Res. 1986;84:626–34.

    Google Scholar 

  29. Verma SK, Bordia A. Effect of Commiphora mukul (gum guggula) in patients with hyperlipidemia with special reference to HDL-cholesterol. Indian J Med Res. 1988;87:356–60.

    CAS  PubMed  Google Scholar 

  30. Philippe O, Szapary PO, Wolfe ML, Bloedon LT, et al. Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial. JAMA. 2003;290:765–72.

    Google Scholar 

  31. Chung KF, Dent G, McCusker M, et al. Effect of a ginkgolide mixture (BN 52063) in antagonising skin and platelet responses to platelet activating factor in man. Lancet. 1987;1:248–51.

    CAS  PubMed  Google Scholar 

  32. Le Bars PL, Katz M, Berman N, et al. A placebo controlled, double blind, randomized trial of an extract of ginkgo biloba for dementia. JAMA. 1997;278:1327–32.

    PubMed  Google Scholar 

  33. Rowin J, Lewis SL. Spontaneous bilateral subdural hematomas associated with chronic ginkgo biloba ingestion. Neurology. 1996;46:1775–6.

    CAS  PubMed  Google Scholar 

  34. Vale S. Subarachnoid haemorrhage associated with ginkgo biloba [Letter]. Lancet. 1998;352:36.

    CAS  PubMed  Google Scholar 

  35. Benjamin J, Muir T, Briggs K, et al. A case of cerebral haemorrhage—can ginkgo biloba be implicated? Postgrad Med J. 2001;77:112–3.

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Rigelsky JM, Sweet BV. Hawthorn: pharmacology and therapeutic uses. Am J Health Syst Pharm. 2002;59:417–22.

    PubMed  Google Scholar 

  37. Aaronson K. HERB-CHF (Hawthorn Extract Randomized Blinded Chronic HF Study). Late-Breaking and Recent clinical Trials. Presented at the 8th Annual Scientific Meeting of the Heart Failure Society of America; September 12-15, 2004; Toronto, ON, Canada.

    Google Scholar 

  38. Holubarsch CJF, Colucci WS, Meinertz T, et al. Crataegus extract WS 1442 postpones cardiac death in patients with congestive heart failure class NYHA II-III: a randomized, placebo-controlled, double-blind trial in 2681 patients. American College of Cardiology 2007 Scientific Sessions March 27, 2007; New Orleans, LA. Late breaking clinical trials-3, Session 414–5.

    Google Scholar 

  39. http://www.ncbi.nlm.nih.gov/books/NBK92775/#ch7_r190

  40. http://www.ncbi.nlm.nih.gov/pubmed/22058071

  41. http://www.ncbi.nlm.nih.gov/pubmed/22481014

  42. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4220499/#ref48

  43. http://www.ncbi.nlm.nih.gov/pubmed/9505018

  44. http://www.ncbi.nlm.nih.gov/pubmed/11225136

  45. http://www.ncbi.nlm.nih.gov/pubmed/14564675

  46. Yang CS, Lu FH, Wu JS, et al. The protective effect of habitual tea consumption on hypertension. Arch Intern Med. 2004;164(14):1534–40. https://doi.org/10.1001/archinte.164.14.1534.

    Article  PubMed  Google Scholar 

  47. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2613497/

  48. http://agris.fao.org/agris-search/search.do?recordID=US19890065227

  49. http://science.naturalnews.com/pubmed/19298191.html

  50. http://www.ncbi.nlm.nih.gov/pubmed/12589329

  51. http://circ.ahajournals.org/content/119/10/1433.full

  52. http://www.journal-of-cardiology.com/article/S0914-5087%2808%2900150-0/abstract

  53. http://www.healthplusweb.com

  54. Tran MT, Mitchell TM, Kennedy DT, et al. Role of coenzyme Q10 in chronic heart failure, angina, and hypertension. Pharmacotherapy. 2001;21:797–806.

    CAS  PubMed  Google Scholar 

  55. Watson PS, Scalia GM, Galbraith A, et al. Lack of effect of coenzyme Q on left ventricular function in patients with congestive heart failure. J Am Coll Cardiol. 1999;33:1549–52.

    CAS  PubMed  Google Scholar 

  56. Khatta M, Alexander BS, Krichten CM, et al. The effect of coenzyme Q10 in patients with congestive heart failure. Ann Intern Med. 2000;132:636–40.

    CAS  PubMed  Google Scholar 

  57. http://www.ncbi.nlm.nih.gov/pubmed/18541825

  58. http://www.ncbi.nlm.nih.gov/pubmed/11705562?dopt=Citation

  59. http://www.ncbi.nlm.nih.gov/pubmed/18339654?dopt=Citation

  60. Institute of Medicine. Dietary reference intakes for calcium and vitamin D. Washington, DC: National Academies Press; 2010.

    Google Scholar 

  61. http://jn.nutrition.org/content/134/11/3100.full.pdf

  62. Calzada C, Bruckdorfer KR, Rice-Evans CA. The influence of antioxidant nutrients on platelet f unction in healthy volunteers. Atherosclerosis. 1997;128:97.

    CAS  PubMed  Google Scholar 

  63. Boscoboinik D, Szewczyk A, Hensey C, et al. Inhibition of cell proliferation by alpha-tocopherol: role of protein kinase C. J Biol Chem. 1991;266:6188.

    CAS  PubMed  Google Scholar 

  64. Stampfer MJ, Hennekens CH, Manson JE, et al. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med. 1993;328:1444.

    CAS  PubMed  Google Scholar 

  65. Rimm EB, Stampfer MJ, Ascherio A, et al. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med. 1993;328:1450.

    CAS  PubMed  Google Scholar 

  66. Kushi LH, Folsom AR, Prineas RJ, et al. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N Engl J Med. 1996;334:1156–62.

    CAS  PubMed  Google Scholar 

  67. The Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med. 2000;342:154–60.

    Google Scholar 

  68. GISSI-Prevenzione Investigators (Gruppo Italiano perlo Studio della Sopravvivenza nell’Infarto Miocardico). Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet. 1999;354:447–55 (Erratum, Lancet 2001;357:342.)

    Google Scholar 

  69. Stephens NG, Parsons A, Schofield PM, et al. Randomized controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 1996;347:781–6.

    CAS  PubMed  Google Scholar 

  70. Collaborative Group of the Primary Prevention Project. Low dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Lancet. 2001;357:89–96.

    Google Scholar 

  71. Lee IM, Cook NR, Gaziano JM, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the women’s health study: a randomized controlled trial. JAMA. 2005;294:56–5.

    CAS  PubMed  Google Scholar 

  72. Rimm EB, Stampfer MJ. Antioxidant for vascular disease. Med Clin North Am. 2000;84:239–49.

    CAS  PubMed  Google Scholar 

  73. Food and Nutrition Board, Institute of Medicine. Dietary reference intake for vitamin C, vitamin E, selenium and carotenoids: a report of the Panel of Dietary Antioxidants and Related Compounds. Washington, DC: National Academy Press; 2000. p. 529.

    Google Scholar 

  74. Marcus R, Coulston AM. The vitamins. In: Gilman AG, Rall TW, Nies AS, et al., editors. Goodman and Gilman’s: the pharmacological basis of therapeutics. 8th ed. New York: Pergamon Press; 1990. p. 1523–71.

    Google Scholar 

  75. Kritchevsky SB. Beta-carotene, carotenoids and the prevention of coronary heart disease. J Nutr. 1999;129:5.

    CAS  PubMed  Google Scholar 

  76. Greenberg ER, Baron JA, Karagas MR, et al. Mortality associated with low plasma concentration of beta carotene and the effect of oral supplementation. JAMA. 1996;275:699.

    CAS  PubMed  Google Scholar 

  77. Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med. 1996;334:1145.

    CAS  PubMed  Google Scholar 

  78. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med. 1996;334:1150.

    CAS  PubMed  Google Scholar 

  79. Malila N, Virtamo J, Virtanen M, Pietinen P, Albanes D, Teppo L. Dietary and serum alpha-locopherol, beta-carotone and retinol, and risk for colorectal cancer in male smokers. [Clinical Trial. Journal Article. Randomized Controlled Trial]. Eur J Clin Nutr. 2002;56(7):615–21.

    CAS  PubMed  Google Scholar 

  80. The Alpha-Tocopherol Beta-Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med. 1994;330:1029.

    Google Scholar 

  81. Kohlmeier L, Kark JD, Gomez-Gracia E, et al. Lycopene and myocardial infarction risk in the EURAMIC Study. Am J Epidemiol. 1997;146:618.

    CAS  PubMed  Google Scholar 

  82. Dwayer JH, Navab M, Dwyer KM, et al. Oxygenated carotenoid lutein and progression of early atherosclerosis. The Los Angeles atherosclerosis study. Circulation. 2001;103:2922–7.

    Google Scholar 

  83. MRC Vitamin Study R search Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet. 1991;338:131–7.

    Google Scholar 

  84. Jacques PF, Selhub J, Bostom AG, et al. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med. 1999;340:1449–54.

    CAS  PubMed  Google Scholar 

  85. Homocysteine Lowering Trialists’ Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. BMJ. 1998;316:894–8.

    Google Scholar 

  86. Tice JA, Ross E, Coxton PG, et al. Cost-effectiveness of vitamin therapy to lower plasma homocysteine levels for the prevention of coronary heart disease effect of grain fortification and beyond. JAMA. 2001;286:936–43.

    CAS  PubMed  Google Scholar 

  87. Schnyder G, Roffi M, Flammer Y, et al. Association of plasma homocysteine level with restenosis after percutaneous coronary angioplasty. Eur Heart J. 2002;23:726–33.

    CAS  PubMed  Google Scholar 

  88. Schnyder G, Roffi M, Pin R, et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med. 2001;345:1593–600.

    CAS  PubMed  Google Scholar 

  89. Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354(15):1567–77.

    CAS  PubMed  Google Scholar 

  90. Bonaa KH, Njolstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354(15):1578–88.

    CAS  PubMed  Google Scholar 

  91. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083660/

  92. http://ije.oxfordjournals.org/content/28/4/645.full.pdf

  93. http://www.ncbi.nlm.nih.gov/pubmed/12796771

  94. http://www.ncbi.nlm.nih.gov/pubmed/22318649?dopt=Abstract

  95. http://www.ncbi.nlm.nih.gov/pubmed/22205313?dopt=Abstract

  96. http://www.ncbi.nlm.nih.gov/pubmed/24330093

  97. Jones ML, Martoni CJ, Prakash S. Oral supplementation with probiotic L. reuteri NCIMB increases mean circulating 25-hydroxyvitamin D: a post hoc analysis of a randomized controlled trial. J Clin Endocrinol Metab. 2013;98(7):2944–51.

    CAS  PubMed  Google Scholar 

  98. http://www.ncbi.nlm.nih.gov/pubmed/22561556

  99. Clarke NE, Clarke CN, Mosher RE. The “in vivo” dissolution of metastatic calcium. An approach to atherosclerosis. Am J Med Sci. 1955;229:142–9.

    CAS  PubMed  Google Scholar 

  100. http://circoutcomes.ahajournals.org/content/7/1/15.short

  101. DCHPResearch/mls_2011_12_projects/Grp13_OUR.pdf

    Google Scholar 

  102. Fugh-Berman A. Herb-drug interactions. Lancet. 2000;355:134–8.

    CAS  PubMed  Google Scholar 

  103. But PP-H. Herbal poisoning caused by adulterants or erroneous substitutes. J Trop Med Hyg. 1994;97:371–4.

    CAS  PubMed  Google Scholar 

  104. Monmaney T. Remedy’s U.S. sales zoom, but quality control lags. St. John’s wort: regulatory vacuum leaves doubt about potency, effects of herb used for depression. Los Angeles Times 1998 Aug 31:xx(col xx).

    Google Scholar 

  105. Chugh SS, McClelland J, Cook J, et al. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial. JAMA. 2005;293:2884–91.

    PubMed  Google Scholar 

  106. Brouwer IA, Zock PL, Camm AJ, et al. Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the Study on Omega-3 Fatty Acids and Ventricular Arrhythmia (SOFA) randomized trial. JAMA. 2006;295:2613–9.

    CAS  PubMed  Google Scholar 

  107. Mozaffarian D, Rimm EB. Fish intake, contaminants, and human health. Evaluating the risks and the benefits. JAMA. 2006;296:1886–99.

    Google Scholar 

  108. Huang WF, Wen K-C, Hsiao M-L. Adulteration by synthetic therapeutic substances of traditional Chinese medicines in Taiwan. J Clin Pharmacol. 1997;37:344–50.

    CAS  PubMed  Google Scholar 

  109. Galluzzi S, Zanetti O, Binetti G, Trabucchi M, Prisoni GB. Coma in a patient with Alzheimer’s disease taking low dose trazodone and gingko biloba. [Letter]. J Neurol Neurosurg Psychiatry. 2000;68(5):679–80.

    CAS  PubMed  PubMed Central  Google Scholar 

  110. Mohutsky MA, Elmer GW. Inhibition of cytochrome P450 in vitro by the herbal product ginkgo biloba. Presented at the 41st Annual Meeting of the American Society of Pharmacognosy, Seattle, WA; 2000.

    Google Scholar 

  111. Breidenbach T, Kliem V, Burg M, et al. Profound drop of cyclosporin A whole blood trough levels caused by St. John’s wort (perforatum). Transplantation. 2000;69:2229–30.

    CAS  PubMed  Google Scholar 

  112. Breidenbach T, Hoffmann MW, Becker T, et al. Drug interaction of St John’s wort with cyclosporin. Lancet. 2000;355:1912.

    CAS  PubMed  Google Scholar 

  113. Barone GW, Gurley BJ, Ketel BL, et al. Drug interaction between St. John’s wort and cyclosporine. Ann Pharmacother. 2000;34:1013–6.

    CAS  PubMed  Google Scholar 

  114. Durr D, Stieger B, Kullak-Ublick GA, et al. St. John’s wort induces intestinal P glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther. 2000;68:598–604.

    CAS  PubMed  Google Scholar 

  115. Cheng TO. St. John’s wort interaction with digoxin [Letter]. Arch Intern Med. 2000;160:2548.

    PubMed  Google Scholar 

  116. Johne A, Brockmoller J, Bauer S, et al. Pharmacokinetic interaction of digoxin with an herbal extract from St. John’s wort (Hypericum perforatum). Clin Pharmacol Ther. 1999;66:338–45.

    CAS  PubMed  Google Scholar 

  117. Yue QY, Bergquist C, Gerden B. Safety of St John’s wort (Hypericum perforatum). Lancet. 2000;355:576–7.

    CAS  PubMed  Google Scholar 

  118. Piscitelli SC, Burstein AH, Chaitt D, et al. Indinavir concentrations and St John’s wort. Lancet. 2000;355:547–8.

    CAS  PubMed  Google Scholar 

  119. Lumpkin MM, Alpert S. Risk of drug interactions with St. John’s wort and indinavir and other drugs [Letter]. Washington, DC: U.S. Food and Drug Administration, Center for Drug Evaluation and Research; 2000. www.fda.gov/cder/drug/advisory/stjwort.htm

    Google Scholar 

  120. Gordon JB. SSRIs and St. John’s wort: possible toxicity? [Letter]. Am Fam Physician. 1998;57:950–3.

    CAS  PubMed  Google Scholar 

  121. Schneck C. St. John’s wort and hypomania [Letter]. J Clin Psychiatry. 1998;59:689.

    CAS  PubMed  Google Scholar 

  122. Vuksan V, Sievenpiper JL, Koo VY, et al. American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus. Arch Intern Med. 2000;160:1009–13.

    CAS  PubMed  Google Scholar 

  123. Sotaniemi EA, Haapakoski E, Rautio A. Ginseng therapy in non-insulin-dependent diabetic patients. Diabetes Care. 1995;18:1373–5.

    CAS  PubMed  Google Scholar 

  124. Janetzky K, Morreale AP. Probable interaction between warfarin and ginseng. Am J Health Syst Pharm. 1997;54:692–3.

    CAS  PubMed  Google Scholar 

  125. Almmeida JC, Grimsley EW. Coma from the health food store: interaction between kava and alprazolam [Letter]. Ann Intern Med. 1996;125:940–1.

    Google Scholar 

Download references

Acknowledgments

Keith Aaronson, MD and Sara Warber, MD are recipients of NIH grant P50AT00011 from the National Center for Complementary and Alternative Medicine, Bethesda, MD.

Author information

Authors and Affiliations

  1. Holistic Healing Heart Center, Burbank, CA, USA

    Cynthia Thaik

  2. Department of Medicine, Sinai Hospital of Baltimore, Baltimore, MD, USA

    Mauro Moscucci

  3. Department of Family Medicine, University of Michigan Medical School, Ann Arbor, MI, USA

    Sara L. Warber

  4. Division of Cardiovascular Medicine, University of Michigan Medical School, Cardiac Transplant Service, Ann Arbor, MI, USA

    Keith D. Aaronson

Authors
  1. Cynthia Thaik
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mauro Moscucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sara L. Warber
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Keith D. Aaronson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cynthia Thaik .

Editor information

Editors and Affiliations

  1. Division of Cardiovascular Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA

    Ragavendra R. Baliga

  2. University of Michigan Health System, Cardiovascular Center, Ann Arbor, MI, USA

    Kim A. Eagle

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Thaik, C., Moscucci, M., Warber, S.L., Aaronson, K.D. (2020). Complementary and Alternative Medicine. In: Baliga, R., Eagle, K. (eds) Practical Cardiology. Springer, Cham. https://doi.org/10.1007/978-3-030-28328-5_34

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-28328-5_34

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-28326-1

  • Online ISBN: 978-3-030-28328-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation